Malignant Fibrous Histiocytoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Malignant Fibrous Histiocytoma – Drugs In Development, 2024 report and make more profitable business decisions.
Malignant fibrous histiocytoma, now termed undifferentiated pleomorphic sarcoma (UPS), is thought to originate from primitive mesenchymal cells, emerging in soft tissue or bone, typically in the extremities or retroperitoneum. Most common in late adulthood, it exhibits a slight male predominance, constituting the most prevalent soft tissue sarcoma. The subtypes include storiform/pleomorphic, myxoid, giant cell, inflammatory, and angiomatoid. Diagnostic imaging, such as computed tomography (CT) or magnetic resonance imaging (MRI), aids in defining disease extent. Predominantly, the treatment approach involves surgical intervention due to the absence of a singular cure for this neoplasm categorized within the undifferentiated/unclassified sarcomas group.
The Malignant Fibrous Histiocytoma drugs in development market research report provide comprehensive information on the therapeutics under development for Malignant Fibrous Histiocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malignant Fibrous Histiocytoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Malignant Fibrous Histiocytoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Malignant Fibrous Histiocytoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Malignant Fibrous Histiocytoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Malignant Fibrous Histiocytoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abbisko Therapeutics Co LtdADC Therapeutics SA
Akeso Inc
AmMax Bio Inc
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CSPC Pharmaceutical Group Ltd
Deciphera Pharmaceuticals Inc
Eisai Co Ltd
Elixiron Immunotherapeutics Inc
Hutchison MediPharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Philogen SpA
Plexxikon Inc
Shenzhen Chipscreen Biosciences Co Ltd
SynOx Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Malignant Fibrous Histiocytoma reports